Chen Huo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Chen Huo has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Jiajia Qu
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Jie Yao
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Lijun Fang
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Mengyu Zhang
Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, China
1 shared publication - Rui Li
Department of Respiratory and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, 250012, China
1 shared publication - Yi Qu
Department of Geriatrics, Qilu Hospital of Shandong University, Jinan 250012, China; Key Laboratory of Cardiovascular Proteomics of Shandong Province, Jinan 250012, China; Jinan Clinical Research Center for Geriatric Medicine (202132001), Jinan 250012, China
1 shared publication
Latest Publications
- Open Access
- 8 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
PRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer
PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.
- 8 February 2026
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 26 (1)
Open AccessPRKD1/EIF5A/β-catenin axis inhibits tumorigenesis and metastasis in non-small-cell lung cancer
PRKD1 is downregulated in non-small-cell lung cancer (NSCLC). Whether and how PRKD1 regulates tumorigenesis and metastasis is previously unknown. Here, we report that PRKD1 negatively regulates β-catenin protein abundance. PRKD1 promotes ubiquitination and degradation of EIF5A. EIF5A upregulates β-catenin and activates the Wnt signaling pathway. Thus, the PRKD1/EIF5A/β-catenin axis modulates the Wnt signaling pathway in NSCLC. Functionally, PRKD1 inhibits cell proliferation and metastasis both in vitro and in vivo. PRKD1 is downregulated and EIF5A is upregulated in NSCLC. Lower PRKD1 and higher EIF5A predict a worse patient survival. Our study suggests that the PRKD1/EIF5A/β-catenin axis is involved in the carcinogenesis of NSCLC and may serve as a new therapeutic target for NSCLC.